MENLO PARK, CA--(Marketwire - Feb 12, 2013) - Corcept Therapeutics Incorporated ( NASDAQ : CORT ), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its unaudited net revenue for the quarter and the year ended December 31, 2012 and cash balance as of December 31. Corcept reported estimated net revenue of $1.4 million for the fourth quarter of 2012 and $3.3 million for the full year. The company's estimated cash and cash equivalents were $93.0 million at year-end. Audited results will be available when the company files its Annual Report on Form 10-K with the Securities and Exchange Commission.